FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037975991> ?p ?o ?g. }

• W2037975991 endingPage "954" @default.
• W2037975991 startingPage "944" @default.
• W2037975991 abstract "Abstract While the apoptosis‐inducing ligand Apo2L/TRAIL is a promising new agent for the treatment of cancer, the sensitivity of cancer cells for induction of apoptosis by Apo2L/TRAIL varies considerably. Identification of agents that can be used in combination with Apo2L/TRAIL to enhance apoptosis in breast cancer cells would increase the potential utility of this agent as a breast cancer therapeutic. Here, we show that the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize Apo2L/TRAIL‐resistant breast cancer cells to Apo2L/TRAIL‐induced apoptosis. Importantly, neither Apo2L/TRAIL alone, nor in combination with SAHA, affected the viability of normal human cells in culture. Apo2L/TRAIL‐resistant MDA‐MB‐231 breast cancer cells, generated by long‐term culture in the continuous presence of Apo2L/TRAIL, were resensitized to Apo2L/TRAIL‐induced apoptosis by SAHA. The sensitization of these cells by SAHA was accompanied by activation of caspase 8, caspase 9 and caspase 3 and was concomitant with Bid and PARP cleavage. The expression of the proapoptotic protein, Bax, increased significantly with SAHA treatment and high levels of Bax were maintained in the combined treatment with Apo2L/TRAIL. Treatment with SAHA increased cell surface expression of DR5 but not DR4. Interestingly, SAHA treatment also resulted in a significant increase in cell surface expression of DcR1. Taken together, our findings indicate that the use of these 2 agents in combination may be effective for the treatment of breast cancer. © 2006 Wiley‐Liss, Inc." @default.
• W2037975991 created "2016-06-24" @default.
• W2037975991 creator A5013717439 @default.
• W2037975991 creator A5020285542 @default.
• W2037975991 creator A5027816106 @default.
• W2037975991 creator A5050075947 @default.
• W2037975991 creator A5057437913 @default.
• W2037975991 creator A5060420333 @default.
• W2037975991 creator A5060765287 @default.
• W2037975991 creator A5065929346 @default.
• W2037975991 creator A5075623882 @default.
• W2037975991 creator A5063179777 @default.
• W2037975991 date "2006-06-01" @default.
• W2037975991 modified "2023-10-10" @default.
• W2037975991 title "The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL" @default.
• W2037975991 cites W1484817497 @default.
• W2037975991 cites W1519814596 @default.
• W2037975991 cites W1567485746 @default.
• W2037975991 cites W1674551699 @default.
• W2037975991 cites W1820010991 @default.
• W2037975991 cites W1971621147 @default.
• W2037975991 cites W1973899902 @default.
• W2037975991 cites W1979003732 @default.
• W2037975991 cites W1982661150 @default.
• W2037975991 cites W1984709119 @default.
• W2037975991 cites W1993227701 @default.
• W2037975991 cites W1995443667 @default.
• W2037975991 cites W1995638825 @default.
• W2037975991 cites W2000225649 @default.
• W2037975991 cites W2002451433 @default.
• W2037975991 cites W2003907016 @default.
• W2037975991 cites W2006978594 @default.
• W2037975991 cites W2016329566 @default.
• W2037975991 cites W2016770760 @default.
• W2037975991 cites W2032077813 @default.
• W2037975991 cites W2034420402 @default.
• W2037975991 cites W2035207372 @default.
• W2037975991 cites W2041946926 @default.
• W2037975991 cites W2045243434 @default.
• W2037975991 cites W2049312704 @default.
• W2037975991 cites W2058561774 @default.
• W2037975991 cites W2059238397 @default.
• W2037975991 cites W2063228846 @default.
• W2037975991 cites W2070164024 @default.
• W2037975991 cites W2073909775 @default.
• W2037975991 cites W2076152655 @default.
• W2037975991 cites W2077793109 @default.
• W2037975991 cites W2078747183 @default.
• W2037975991 cites W2081651746 @default.
• W2037975991 cites W2085233944 @default.
• W2037975991 cites W2087057471 @default.
• W2037975991 cites W2088580558 @default.
• W2037975991 cites W2089458132 @default.
• W2037975991 cites W2089476060 @default.
• W2037975991 cites W2092196409 @default.
• W2037975991 cites W2092508425 @default.
• W2037975991 cites W2098617365 @default.
• W2037975991 cites W2105186639 @default.
• W2037975991 cites W2106284224 @default.
• W2037975991 cites W2117963070 @default.
• W2037975991 cites W2130407652 @default.
• W2037975991 cites W2149386327 @default.
• W2037975991 cites W2156870300 @default.
• W2037975991 cites W2164658809 @default.
• W2037975991 cites W2165074091 @default.
• W2037975991 cites W2167118090 @default.
• W2037975991 cites W2320692584 @default.
• W2037975991 cites W4235389785 @default.
• W2037975991 cites W4251934001 @default.
• W2037975991 doi "https://doi.org/10.1002/ijc.21939" @default.
• W2037975991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16550602" @default.
• W2037975991 hasPublicationYear "2006" @default.
• W2037975991 type Work @default.
• W2037975991 sameAs 2037975991 @default.
• W2037975991 citedByCount "64" @default.
• W2037975991 countsByYear W20379759912012 @default.
• W2037975991 countsByYear W20379759912013 @default.
• W2037975991 countsByYear W20379759912014 @default.
• W2037975991 countsByYear W20379759912015 @default.
• W2037975991 countsByYear W20379759912016 @default.
• W2037975991 countsByYear W20379759912017 @default.
• W2037975991 countsByYear W20379759912018 @default.
• W2037975991 countsByYear W20379759912019 @default.
• W2037975991 countsByYear W20379759912020 @default.
• W2037975991 countsByYear W20379759912021 @default.
• W2037975991 countsByYear W20379759912022 @default.
• W2037975991 countsByYear W20379759912023 @default.
• W2037975991 crossrefType "journal-article" @default.
• W2037975991 hasAuthorship W2037975991A5013717439 @default.
• W2037975991 hasAuthorship W2037975991A5020285542 @default.
• W2037975991 hasAuthorship W2037975991A5027816106 @default.
• W2037975991 hasAuthorship W2037975991A5050075947 @default.
• W2037975991 hasAuthorship W2037975991A5057437913 @default.
• W2037975991 hasAuthorship W2037975991A5060420333 @default.
• W2037975991 hasAuthorship W2037975991A5060765287 @default.
• W2037975991 hasAuthorship W2037975991A5063179777 @default.
• W2037975991 hasAuthorship W2037975991A5065929346 @default.
• W2037975991 hasAuthorship W2037975991A5075623882 @default.

• next